K I Ataga

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi request reprint Pulmonary hypertension in sickle cell disease
    Kenneth I Ataga
    Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
    Am J Med 117:665-9. 2004
  2. pmc Association of coagulation activation with clinical complications in sickle cell disease
    Kenneth I Ataga
    Division of Hematology Oncology, University of North Carolina, Chapel Hill, North Carolina, United States of America
    PLoS ONE 7:e29786. 2012
  3. doi request reprint Association of soluble fms-like tyrosine kinase-1 with pulmonary hypertension and haemolysis in sickle cell disease
    Kenneth I Ataga
    Comprehensive Sickle Cell Program Division of Hematology Oncology Department of Biochemistry and Biophysics Department of Biostatistics Department of Pediatrics, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Br J Haematol 152:485-91. 2011
  4. pmc Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1
    Kenneth I Ataga
    Comprehensive Sickle Cell Program, University of North Carolina, Chapel Hill, NC, USA
    Eur J Haematol 85:257-63. 2010
  5. ncbi request reprint Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia
    Kenneth I Ataga
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Room 3149, Physicians Office Building, CB 7305, Chapel Hill, NC 27599 7305, USA
    Expert Opin Investig Drugs 18:231-9. 2009
  6. doi request reprint Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia
    Kenneth I Ataga
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB no 7305, 3009 Old Clinic Bldg, Chapel Hill, NC 27599 7305, USA
    Blood 111:3991-7. 2008
  7. doi request reprint Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension
    Kenneth I Ataga
    Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Bldg Chapel Hill, NC 27599 7305, USA
    Haematologica 93:20-6. 2008
  8. ncbi request reprint Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability
    Kenneth I Ataga
    Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Br J Haematol 139:3-13. 2007
  9. ncbi request reprint Dose-escalation study of ICA-17043 in patients with sickle cell disease
    Kenneth I Ataga
    Division of Hematology Oncology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    Pharmacotherapy 26:1557-64. 2006
  10. ncbi request reprint Pulmonary hypertension in patients with sickle cell disease: a longitudinal study
    Kenneth I Ataga
    Division of Hematology Oncology and Comprehensive Sickle Cell Program, University of North Carolina, Chapel Hill, NC, USA
    Br J Haematol 134:109-15. 2006

Research Grants

  1. DISORDERED BLOOD COAGULATION IN SICKLE CELL DISEASE
    Kenneth Ataga; Fiscal Year: 2006
  2. COAGULATION ACTIVATION IN SICKLE CELL DISEASE
    Kenneth Ataga; Fiscal Year: 2009
  3. COAGULATION ACTIVATION IN SICKLE CELL DISEASE
    Kenneth I Ataga; Fiscal Year: 2010

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Pulmonary hypertension in sickle cell disease
    Kenneth I Ataga
    Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
    Am J Med 117:665-9. 2004
    ..We sought to determine the prevalence of pulmonary hypertension in adult patients with sickle cell disease and to identify factors associated with this life-threatening complication...
  2. pmc Association of coagulation activation with clinical complications in sickle cell disease
    Kenneth I Ataga
    Division of Hematology Oncology, University of North Carolina, Chapel Hill, North Carolina, United States of America
    PLoS ONE 7:e29786. 2012
    ..We sought to evaluate the association of markers of coagulation and platelet activation with specific clinical complications and laboratory variables in patients with SCD...
  3. doi request reprint Association of soluble fms-like tyrosine kinase-1 with pulmonary hypertension and haemolysis in sickle cell disease
    Kenneth I Ataga
    Comprehensive Sickle Cell Program Division of Hematology Oncology Department of Biochemistry and Biophysics Department of Biostatistics Department of Pediatrics, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Br J Haematol 152:485-91. 2011
    ..By inducing endothelial dysfunction, sFLT-1 may contribute to the pathogenesis of SCD-associated PHT, although this effect does not appear to be independent of haemolysis...
  4. pmc Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1
    Kenneth I Ataga
    Comprehensive Sickle Cell Program, University of North Carolina, Chapel Hill, NC, USA
    Eur J Haematol 85:257-63. 2010
    ..The purpose of this exploratory study was to determine the relationship between albuminuria and both clinical and laboratory variables in SCD...
  5. ncbi request reprint Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia
    Kenneth I Ataga
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Room 3149, Physicians Office Building, CB 7305, Chapel Hill, NC 27599 7305, USA
    Expert Opin Investig Drugs 18:231-9. 2009
    ....
  6. doi request reprint Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia
    Kenneth I Ataga
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB no 7305, 3009 Old Clinic Bldg, Chapel Hill, NC 27599 7305, USA
    Blood 111:3991-7. 2008
    ..This study is registered at http://clinicaltrials.gov as NCT00040677...
  7. doi request reprint Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension
    Kenneth I Ataga
    Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Bldg Chapel Hill, NC 27599 7305, USA
    Haematologica 93:20-6. 2008
    ..Pulmonary hypertension (PHT) is common in sickle cell disease (SCD). The purpose of this study was to determine whether markers of coagulation activation and inflammation are associated with PHT in SCD...
  8. ncbi request reprint Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability
    Kenneth I Ataga
    Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Br J Haematol 139:3-13. 2007
    ....
  9. ncbi request reprint Dose-escalation study of ICA-17043 in patients with sickle cell disease
    Kenneth I Ataga
    Division of Hematology Oncology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    Pharmacotherapy 26:1557-64. 2006
    ..To determine the dose tolerance, safety, and pharmacokinetics of a single oral dose of ICA-17043 in patients with sickle cell disease...
  10. ncbi request reprint Pulmonary hypertension in patients with sickle cell disease: a longitudinal study
    Kenneth I Ataga
    Division of Hematology Oncology and Comprehensive Sickle Cell Program, University of North Carolina, Chapel Hill, NC, USA
    Br J Haematol 134:109-15. 2006
    ....
  11. ncbi request reprint Renal abnormalities in sickle cell disease
    K I Ataga
    Division of Hematology Oncology, Department of Medicine, UNC Comprehensive Sickle Cell Program and General Clinical Research Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Am J Hematol 63:205-11. 2000
    ..Finally, progression of sickle cell nephropathy to ESRD may be slowed by adequate control of hypertension and proteinuria. However, the prevention of the renal complications of SCD will require a cure for this genetic disorder...
  12. ncbi request reprint Hypercoagulability in sickle cell disease: a curious paradox
    Kenneth I Ataga
    Division of Hematology Oncology, Department of Medicine, University of North Carolina Comprehensive Sickle Cell Program, Chapel Hill, North Carolina 27599 7305, USA
    Am J Med 115:721-8. 2003
    ..This review discusses hypercoagulability in the various forms of sickle cell disease, including homozygous sickle cell anemia, hemoglobin SC disease, hemoglobin SD disease, and sickle cell-beta-thalassemia...
  13. ncbi request reprint Renal cell carcinoma
    P A Godley
    University of North Carolina at Chapel Hill, Division of Hematology Oncology and the Lineberger Comprehensive Cancer Center, Chapel Hill 27599 7305, USA
    Curr Opin Oncol 12:260-4. 2000
    ..In addition, patients with deletion (8p)/-8, +12, and +20 appear to have a worse prognosis...
  14. pmc Placenta growth factor in sickle cell disease: association with hemolysis and inflammation
    Julia E Brittain
    Department of Biochemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
    Blood 115:2014-20. 2010
    ..Prospective studies are required to conclusively define the contribution of PlGF to the pathogenesis of PHT and other hemolytic complications in SCD...
  15. ncbi request reprint Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial
    E P Orringer
    School of Medicine, University of North Carolina at Chapel Hill, Room 125, MacNider Bldg, CB7000, Chapel Hill, NC 27599 7000, USA
    JAMA 286:2099-106. 2001
    ..Purified poloxamer 188 may increase tissue oxygenation and thereby reduce inflammation, pain, and the overall duration of such painful episodes in patients with SCD...
  16. pmc Delayed hemolytic transfusion reaction in sickle cell disease
    Leslie P Scheunemann
    Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    Am J Med Sci 339:266-9. 2010
    ..It is important that delayed hemolytic transfusion reactions be included in the differential diagnosis of acute pain episodes following a red blood cell transfusion in a patient with sickle cell disease...
  17. ncbi request reprint Hypercoagulability in sickle cell disease and beta-thalassemia
    Sylvia T Singer
    Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC, USA
    Curr Mol Med 8:639-45. 2008
    ..Furthermore, adequately controlled studies using anticoagulants and antiplatelet agents are warranted to define the role of hypercoagulability in specific complications of these diseases...
  18. ncbi request reprint Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation
    Sheritha P Lee
    Department of Pharmacology, University of North Carolina, CB 7365, Chapel Hill, NC 27599 7365, USA
    Arterioscler Thromb Vasc Biol 26:1626-31. 2006
    ..Because sickle cell anemia (SCA) is noted for both platelet activation and chronic inflammation, we asked whether platelet-released CD40L potentially plays a role in SCA...
  19. pmc Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease
    Allison E Ashley-Koch
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Blood 111:5721-6. 2008
    ..These findings may offer new promise for identifying patients at risk for pHTN, developing new therapeutic targets, and reducing the occurrence of this life-threatening SCD complication...
  20. ncbi request reprint Mechanism of CD47-induced alpha4beta1 integrin activation and adhesion in sickle reticulocytes
    Julia E Brittain
    Department of Pharmacology, University of North Carolina at Chapel Hill, 27599 7365, USA
    J Biol Chem 279:42393-402. 2004
    ..These studies therefore identify the alpha4beta1 integrin on SS RBCs as a CD47-activated receptor for TSP, VCAM-1, and plasma fibronectin, revealing novel binding characteristics of this integrin...
  21. ncbi request reprint Phase I study of eptifibatide in patients with sickle cell anaemia
    Sheritha P Lee
    Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7365, USA
    Br J Haematol 139:612-20. 2007
    ..Based on these phase I results, eptifibatide may benefit SCA patients by inhibiting platelet aggregation, decreasing sCD40L levels and favourably altering plasma levels of inflammatory mediators...
  22. ncbi request reprint Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion
    Patrick C Hines
    Department of Pharmacology, University of North Carolina at Chapel Hill, 27599, USA
    Blood 101:3281-7. 2003
    ....
  23. ncbi request reprint Genetic polymorphisms associated with priapism in sickle cell disease
    Laine Elliott
    Department of Medicine, Duke University and VA Medical Centers, Durham, NC 27710, USA
    Br J Haematol 137:262-7. 2007
    ..Our data suggest that genes involved in the TGFbeta pathway, coagulation, cell adhesion and cell hydration pathways may be important in risk for priapism...
  24. ncbi request reprint Role of Rap1 in promoting sickle red blood cell adhesion to laminin via BCAM/LU
    Meghan M Murphy
    Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Blood 105:3322-9. 2005
    ..These results demonstrate that Epac-induced Rap1 activation in SS RBCs promotes BCAM/LU-mediated adhesion to laminin. Thus, Epac-mediated Rap1 activation may represent an important signaling pathway for promoting SS RBC adhesion...
  25. doi request reprint Fibronectin bridges monocytes and reticulocytes via integrin alpha4beta1
    Julia E Brittain
    Departments of Pharmacology, and Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, NC, USA
    Br J Haematol 141:872-81. 2008
    ....

Research Grants8

  1. DISORDERED BLOOD COAGULATION IN SICKLE CELL DISEASE
    Kenneth Ataga; Fiscal Year: 2006
    ..e., is the "hypercoagulability" observed in patients with SCD a primary cause of the vasoocclusion or is it simply a secondary event that is observed in this clinical setting. ..
  2. COAGULATION ACTIVATION IN SICKLE CELL DISEASE
    Kenneth Ataga; Fiscal Year: 2009
    ..abstract_text> ..
  3. COAGULATION ACTIVATION IN SICKLE CELL DISEASE
    Kenneth I Ataga; Fiscal Year: 2010
    ..abstract_text> ..